Adaptimmune Therapeutics Ownership
| ADAP Stock | USD 0.64 0.02 3.03% |
Shares in Circulation | First Issued 2014-09-30 | Previous Quarter 259.9 M | Current Value 255.8 M | Avarage Shares Outstanding 141.1 M | Quarterly Volatility 73.6 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Adaptimmune |
Adaptimmune Stock Ownership Analysis
About 60.0% of the company shares are held by institutions such as insurance companies. The book value of Adaptimmune Therapeutics was presently reported as 0.17. The company has Price/Earnings To Growth (PEG) ratio of 0.11. Adaptimmune Therapeutics recorded a loss per share of 0.17. The entity last dividend was issued on the 30th of March 2018. Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom. Adaptimmune Ther operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 494 people. For more info on Adaptimmune Therapeutics Plc please contact Adrian Rawcliffe at 44 12 3543 0000 or go to https://www.adaptimmune.com.Besides selling stocks to institutional investors, Adaptimmune Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Adaptimmune Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Adaptimmune Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Adaptimmune Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Less than 1% of Adaptimmune Therapeutics Plc are currently held by insiders. Unlike Adaptimmune Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Adaptimmune Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Adaptimmune Therapeutics' insider trades
Adaptimmune Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Adaptimmune Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Adaptimmune Therapeutics Plc backward and forwards among themselves. Adaptimmune Therapeutics' institutional investor refers to the entity that pools money to purchase Adaptimmune Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Fmr Inc | 2024-09-30 | 1.7 M | Renaissance Technologies Corp | 2024-09-30 | 1.7 M | Jpmorgan Chase & Co | 2024-06-30 | 1 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 881.7 K | Millennium Management Llc | 2024-06-30 | 779.6 K | Redmile Group, Llc | 2024-09-30 | 715.6 K | Acuitas Investments, Llc | 2024-06-30 | 541.2 K | Rathbone Brothers Plc | 2024-06-30 | 432.8 K | State Street Corp | 2024-06-30 | 390.9 K | Matrix Capital Management Company, Llc | 2024-06-30 | 39 M | Ecor1 Capital, Llc | 2024-06-30 | 27.4 M |
Adaptimmune Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Adaptimmune Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Adaptimmune Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Adaptimmune Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Adaptimmune Therapeutics Outstanding Bonds
Adaptimmune Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Adaptimmune Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Adaptimmune bonds can be classified according to their maturity, which is the date when Adaptimmune Therapeutics Plc has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| ADAPTHEALTH LLC 6125 Corp BondUS00653VAA98 | View | |
| AdaptHealth LLC 4625 Corp BondUS00653VAC54 | View | |
| US00653VAE11 Corp BondUS00653VAE11 | View |
Pair Trading with Adaptimmune Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Adaptimmune Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Adaptimmune Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Adaptimmune Stock
Moving against Adaptimmune Stock
| 0.85 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.84 | PRAX | Praxis Precision Med | PairCorr |
| 0.83 | AMLX | Amylyx Pharmaceuticals | PairCorr |
| 0.7 | VRDN | Viridian Therapeutics | PairCorr |
| 0.7 | AKRO | Akero Therapeutics | PairCorr |
The ability to find closely correlated positions to Adaptimmune Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Adaptimmune Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Adaptimmune Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Adaptimmune Therapeutics Plc to buy it.
The correlation of Adaptimmune Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Adaptimmune Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Adaptimmune Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Adaptimmune Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Adaptimmune Stock Analysis
When running Adaptimmune Therapeutics' price analysis, check to measure Adaptimmune Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptimmune Therapeutics is operating at the current time. Most of Adaptimmune Therapeutics' value examination focuses on studying past and present price action to predict the probability of Adaptimmune Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptimmune Therapeutics' price. Additionally, you may evaluate how the addition of Adaptimmune Therapeutics to your portfolios can decrease your overall portfolio volatility.